Electrically mediated drug delivery for treating subcutaneous and orthotopic pancreatic adenocarcinoma in a hamster model

Anticancer Research

Volumn 19, Issue 2 A, 1999, Pages 989-994

  Jaroszeski, Mark J ^a   Illingworth, Philip ^a   Pottinger, Carlos ^a   Hyacinthe, Micheline ^b   Heller, Richard ^c,d  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c University of South Florida   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Bleomycin; Cisplatin; Electrochemotherapy; Pancreatic adenocarcinoma; Pancreatic cancer

Indexed keywords

BLEOMYCIN; CISPLATIN; DOXORUBICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CELL SURVIVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ELECTROCHEMOTHERAPY; HAMSTER; MALE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CRICETINAE; DRUG DELIVERY SYSTEMS; ELECTRODES; MALE; MESOCRICETUS; PANCREATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033029346     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. American Cancer Society, Inc. Cancer Statistics 1995, Cancer 45(1), 1995.
2. MacDonald JS: Pancreatic Cancer. Seminars in Oncology 23(2): 199, 1996.
3. Ashley SW, Reber HA: Surgical management of exocrine pancreatic cancer. In: The Pancreas: Biology Pathobiology, ans Disease, second ed., pp. 913-929, Raven Press, Ltd., New York, 1993.
4. Carriaga MT and Henson DE: Liver, gallbladder, extrahepatic bile duct and pancreas. Cancer 75: 171-190, 1995.
5. Bell BH, Jr: Neoplasms ofthe exocrine pancreas in Surgery: Scientific Principles and Practice (Greenfield, L.J, ed.), pp. 816-830, J.B. Lippincott Company, Philadelphia, 1993.
6. Nagakawa T, Nagamori M, Futakami F et al: Results of extensive surgery for pancreatic carcinoma. Cancer 77: 640-645, 1996.
7. Moehtel CG, Frytak S, Hahn RF et al: Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluoruracil. Cancer 48: 1705-1710, 1981.
8. Mir LM, Banoun H, and Paoletti C: Introduction of definite amounts of nonpermeant molecules into living cells after electropermeabilization: direct access to the cytosol. Exp Cell Res 175: 15-25, 1988.
9. Orlowski S, Belehradek J Jr, Paoletti C, and Mir LM: Transient electropermeabilization of cells in culture. Biochem Pharm 37(24): 4727-4733, 1988.
10. Heller R, Jaroszeski M, Leo-Messina J, Perrott R, Van Voorhis N, Reintgen D, and Gilbert R: Treatment of B16 melanoma with the combination of electroporation and chemotherapy. Bioelectrochem Bioenerget 36: 83-87, 1995.
11. Heller R, Jaroszeski M, Perrott R, Messina J, and Gilbert R: Effective treatment of B16 melanoma by direct delivery of bleomycin using electrochemotherapy. Melanoma Res 7: 10-18, 1997.
12. Sersa G, Cemazar M, Miclavcic D, and Mir LM: Electrochemotherapy: variable anti-tumor effect on different tumor models. Bioelectrochem. Bioenerget 35: 23-27, 1994.
13. Mir LM, Orlowski S, Belehradek J Jr, and Paoletti C: Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 27(1): 68-72, 1991.
14. Pendez S, Jaroszeski M J, Gilbert R Hyacinthe M, Dang V, Hickey J, Pottinger C, Illingworth P and Heller R: Direct delivery of chemotherapeutic agents for the treatment of hepatomas and sarcomas in rat models. Radiology and Oncology 21(1): 53-64, 1998.
15. Sersa G, Novakovic S, and Miklavcic D: Potentiation of bleomycin antitumor effectiveness by electrotherapy. CancerLetters 69: 81-84, 1993.
16. Nanda GS, Sun FX, Hofmann GA, Hoffman RM, and Dev SB: Electroporation enhances therapeutic efficacy of anticancer drugs: treatment of human pancreatic tumor in animal model. Anticancer Research 18: 1361-1366, 1998.
17. Heller R Jaroszeski MJ, Glass LF, Messina JL, Rapaport DP, DeConti RC, Fenske NA, Gilbert RA, Mir LM, and Reintgen DS: Phase I/II trial for the treatment of cutaneous and subcutaneous tumors using electrochemotherapy. Cancer 77(5): 964-971, 1996.
18. Glass LF, Fenske NA, Jaroszeski MJ, Perott R, Harvey DT, Reintgen DS, and Heller R: Bleomycin-mediated electrochemotherapy of basal cell carcinoma J Am Acad Derm 34(1): 82-86, 1996.
19. Glass LF, Pepine ML, Fenske NA, Jaroszeski MJ, Reintgen DS, and Heller R: Bleomycin-mediated electrochemotherapy of metastatic melanoma. Archiv Derm 156: 1353-1357, 1996.
20. Heller R, Jaroszeski MJ, Reintgen DS, Puleo CA, DeConti RC, Gilbert RA and Glass LF: Treatment of cutaneous tumors with electrochemotherapy using intralesional bleomcyin. Cancer 83(1): 148-157, 1998.
21. Mir LM, Belehradek M, Domenge C, Orlowski S, Poddevin J Jr, Schwab G, Luboinnski B, and Paoletti C: Electrochemotherapy, a novel antitumor treatment: first clinical trial. C R Acad Sci Paris 313: 613-618, 1991.
22. Belehradek M, Domenge C, Luboinnski B, Orlowski S, Belehradek J, and Mir LM: Electrochemotherapy, a new antitumor treatment. Cancer 72(12): 3694-3700, 1993.
23. Domenge C, Orlowski S, Luboinski B, DeBaere T, Schwaab G, Belehradek J Jr, and Mir LM: Antitumor electrochemotherapy. Cancer 77(5): 956-963, 1996.
24. Rudolf Z, Stabuc B, Cemazar M, Miklavcic D, Vodovnik L, Sersa G: Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients. Radiology and Oncology 29: 229-235, 1995.
25. Sersa G, Stabuc B, Cemazar M, Jancar B, Miklavcic D, and Rudolf Z: Electrochemotherapy with Cisplatin: potentiation of local Cisplatin antitumor effectiveness by application of electric pulses in cancer patients. European Journal of Cancer (in Press), 1998.
26. Mir LM, Glass LF, Sersa G, Teissie J, Domenge C, Miklavcic D, Jaroszeski MJ, Orlowski S, Reintgen DS, Rudolf Z, Belehradek M, Gilbert R, Rols M-P, Belehradek J Jr, Bachaud JM, DeConti R, Stabuc B, Cemazar M, Coninx P, and Heller R: Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy. British Journal of Cancer 77(12): 2336-2342, 1998.
27. Jaroszeski MJ, Gilbert R, Heller R: In vivo antitumor effects of electrochemotherapy in a hepatoma model. Bioch Biophys Acta 1334: 15-18, 1997.
28. Ramirez LH, Orlowski S, An D, Gindoula G, Dzodic R, Ardouin P, Bognel C, Belehradek J Jr, Munck J-N, and Mir LM, Electrochemotherapy on liver tumours in rabbits. British Journal of Cancer 77(12): 2104-2111, 1998.
29. Hofmann GA, Dev SB, and Nanda GS: Electrochemotherapy: translation from laboratory to the clinic. IEEE Eng Med Biol 15(6): 124-132, 1996.
30. Gehl J, Skowsgaard T, and Mir LM: Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anti-CancerDrugs 9: 319-325, 1998.
31. Egami H, Takiyama Y, Cano M, Houser WH and Pour PM: Establishment of hamster pancreatic ductal carcinoma cell line (PC-1) producing blood group-related antigens. Carcinogenesis 10: 861-869, 1989.
32. Egami H, Tomioka T, Tempero M, Kay D, and Pour PM: Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian Golden Hamsters. Am J Path 138(3): 557-561, 1991.
33. Egami H, Takiyama Y, and Pour PM: Induction of multifocal pancreatic cancer after inoculation of hamster pancreatic cancer cell line (PC-1) into a defined area of homologous tissue. Cancer Letters 50: 53-56, 1990.
34. Hall PA and Lemoine HR: Models of Pancreatic Cancer in Cancer Surveys Volume 16: The Molecular Pathology of Cancer. The Imperial Cancer Research Fund, UK, 1993.
35. Frazier ML andLongnecker DS: Cell lines ofthe human and rodent exocrine pancreas: 17te pancreas: Biology, Pathobiology and Disease (V. Liang W. Go et. al. eds.). 2nd ed, Raven Press, Ltd, New York, 1993.